1. The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells
- Author
-
Peter W. Andrews, Ivana Barbaric, Nissim Benvenisty, Jonathan S. Draper, Tenneille Ludwig, Florian T. Merkle, Yoji Sato, Claudia Spits, Glyn N. Stacey, Haoyi Wang, Martin F. Pera, Faculty of Medicine and Pharmacy, Basic (bio-) Medical Sciences, and Reproduction and Genetics
- Subjects
Epigenomics ,Pluripotent Stem Cells ,safety assessment ,Oncogenes ,genetic integrity ,Cell Biology ,Stem Cell Research ,Cell therapy ,Epigenesis, Genetic ,disease modeling ,Genetics ,Humans ,human pluripotent stem cell ,Molecular Medicine ,tumor formation ,reproductive medicine - Abstract
It is well established that human pluripotent stem cells (hPSCs) can acquire genetic and epigenetic changes during culture in vitro. Given the increasing use of hPSCs in research and therapy and the vast expansion in the number of hPSC lines available for researchers, the International Society for Stem Cell Research has recognized the need to reassess quality control standards for ensuring the genetic integrity of hPSCs. Here, we summarize current knowledge of the nature of recurrent genetic and epigenetic variants in hPSC culture, the methods for their detection, and what is known concerning their effects on cell behavior in vitro or in vivo. We argue that the potential consequences of low-level contamination of cell therapy products with cells bearing oncogenic variants are essentially unknown at present. We highlight the key challenges facing the field with particular reference to safety assessment of hPSC-derived cellular therapeutics.
- Published
- 2022
- Full Text
- View/download PDF